Exclusive client content Select category

close

Choose a category.

• CEO Updates
• Core Offerings
• Leadership Events
• Media
• Observations
• Podcasts
• Special Reports
• Webinars

Blackstone Life Sciences combines deep scientific expertise with premier industry partnerships to provide product financing and equity solutions for late-stage clinical development, spanning pharmaceuticals, biotechnology, medical devices, diagnostics, and life science tools.

It might read a tad counterintuitive but make no mistake, recent events are arguably the most instructive, and bullish, we have seen for some time. And it has nothing to do with geopolitics (if anything, they continue to make the investing picture murkier), the direction of interest rates...

Heading into 2026, we maintain a constructive but increasingly selective outlook. A noisy backdrop of tariffs, trade disputes, snap elections and policy brinkmanship has so far proved largely surmountable for markets, with equities grinding higher and key assets such as oil looking through...

In this month's Core Offerings, we briefly assess how H1 2024 has evolved relative to our expectations.

In the latest episode of The Astute Investor, LGT Wealth Management CIO Scott Haslem speaks with Stephen Halmarick, Principal and Chief Economist at Economics Unchained and former Chief Economist of the Commonwealth Bank of Australia, about the macro backdrop as we enter 2026.

In recent years, we aimed to position portfolios with the intention of protecting against a stressed market environment.